Bardan Marius-Vasile is a multidisciplinary scholar with a strong passion for both scientific and humanistic fields. He completed his high school education with a theological profile and later pursued studies at the Faculty of Theology at “Andrei Șaguna” University of Sibiu. Driven by a deep curiosity, he has expanded his academic interests across multiple domains including chemistry, physics, engineering, psychology, law, and theology. His educational journey reflects continuous self-improvement and autodidactic learning. He has attended several faculties and post-university programs, gaining interdisciplinary knowledge and analytical skills. His academic experience includes participation in both national and international conferences, where he has presented research and developed strong communication abilities. He is recognized for his leadership qualities, teamwork skills, and attention to detail, as well as his ability to manage complex projects and responsibilities effectively. Bardan is adaptable and motivated, with a strong commitment to personal and professional growth. He combines creativity with technical understanding, enabling him to develop innovative and practical solutions. His interests extend to architecture, design, engineering, and visual arts, where he demonstrates strong capabilities in composition, illustration, and conceptual design. He is currently furthering his development through continuous learning and advanced studies, with the goal of contributing meaningfully to interdisciplinary fields.

Serum determinations in SARS COV 2 infection Purpose: This presentation outlines the technical specifications, procedural guidelines, and clinical performance data for the VIDAS® SARS-CoV-2 IgG II (9COG) assay (pp. 1-2). The test serves as an automated diagnostic aid to evaluate whether an individual has developed a specific humoral immune response following exposure to the SARS-CoV-2 virus or vaccination (pp. 2, 4). Methodology: The assay utilizes the Enzyme Linked Fluorescent Assay (ELFA) technique, combining a two-stage sandwich enzyme immunoassay with automated fluorescence detection via a specialized Solid Phase Receptacle (SPR) device (pp. 2, 5). The inner wall of the SPR is coated with recombinant receptor-binding domain (RBD) of the viral Spike protein to capture specific IgG antibodies from human serum or plasma (pp. 2, 7). Alkaline phosphatase-labeled anti-human IgG antibodies and a 4-methylumbelliferyl phosphate substrate are then introduced to generate a measurable fluorescent signal (pp. 6, 11). Performance and Results: The automated analysis delivers semi-quantitative index results within approximately 27 minutes (pp. 2, 24). The test is highly precise and exhibits a wide linear range between 0.40 and 17.00 index values, with a determined cut-off value of 1.00 index equivalent to 20.33 BAU/ml relative to the first WHO international standard (pp. 27, 29, 31). Clinical evaluations demonstrate an overall internal specificity of 99.9% (p. 39). Clinical sensitivity is strongly correlated with time elapsed post-infection, rising from 45.3% within the first 7 days following a positive PCR result to 96.6% after 16 or more days (p. 40). Cross-reactivity studies against a panel of 261 potentially interfering infectious conditions verified high analytical specificity with minimal cross-reactivity (pp. 35-36). Conclusion: The VIDAS® SARS-CoV-2 IgG II assay provides a highly efficient, reliable, and standardized solution for clinical laboratories to quantify anti-RBD Spike protein IgG antibodies, facilitating accurate long-term humoral immunity assessment (pp. 2, 4). Key Words: SARS-CoV-2, Immunoglobulin G (IgG), Enzyme Linked Fluorescent Assay (ELFA), Receptor Binding Domain (RBD), Spike Protein, VIDAS® Automation, Humoral Immunity, Clinical Sensitivity, Analytical Specificity